Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C.

ABSTRACT:

Introduction

In hepatitis C (HCV) patients, obesity and/or diabetes may increase the risk of liver-related outcomes. We aimed to determine whether diabetes and/or obesity are associated with adverse outcomes in direct-acting antiviral (DAA)-treated HCV patients.

Methods

We conducted a retrospective study of 33,003 HCV-infected, DAA-treated Veterans between 2013 and 2015. Body mass index was used to categorize patients into underweight (< 18.5 kg/m²), normal weight (18.5 to < 25 kg/m²), overweight (25 to < 30 kg/m²), obesity I (30 to < 35 kg/m²), and obesity II-III (> 35 kg/m²). Diabetes was defined by ICD-9/10 codes in association with hemoglobin A1c > 6.5% or medication prescriptions. Patients were followed from 180 day

SUBMITTER: Benhammou JN 

PROVIDER: S-EPMC7854862 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature